Methods | Statistics | Clinical | Educational | Industrial | Professional items | World psychology |
Therapeutic hypothermia is a medical treatment method which clinically uses the advantages of a lower body temperature. Therapeutic hypothermia can be used to treat revived (i.e. resuscitated) cardiac arrest victims. The new treatment method is able to reduce mortality of successfully resuscitated cardiac arrest victims by 35 percent and increase the chance of a good neurologic outcome by 39 percent[How to reference and link to summary or text]. Every sixth time a cardiac arrest patient is treated with therapeutic hypothermia, physicians can rescue one life. As cardiac arrest is the most common cause of death in the industrialized world, therapeutic hypothermia has the power to save an enormous number of patients.[How to reference and link to summary or text]
In addition, there exists a growing body of evidence that hypothermia increases survival chances and quality for patients suffering from other ischemic insults such as stroke or generalized brain trauma[How to reference and link to summary or text]. Hypothermia can also be used to manage fever in patients suffering neurological injuries.
Hypothermia has been applied therapeutically since antiquity. The Greek physician Hippocrates, the namesake of the Hippocratic Oath and arguably the world’s first modern doctor, advocated the packing of wounded soldiers in snow and ice. Napoleonic surgeon Baron Dominque Larrey recorded that officers, who were kept closer to the fire, survived less often than the minimally pampered infantrymen. In modern times the first medical article concerning hypothermia was published in 1945.This study focused on the effects of hypothermia on patients suffering from severe head injury. In the 1950’s hypothermia received its first medical application, being used in intracerebal aneurysm surgery to create a bloodless field.  Most of the early research focused on the applications of deep hypothermia, defined as a body temperature between 20-25 °C (68-77 °F). Such an extreme drop in body temperature brings with it a whole host of side effects, side effects which made the use of deep hypothermia impractical in most clinical situations.
This period also saw sporadic investigation of more mild forms of hypothermia, with mild hypothermia being defined as a body temperature between 32-34°C (89.6-93.2°F). In the 1950’s Doctor Rosomoff demonstrated in dogs the positive effects of mild hypothermia after brain ischemia and traumatic brain injury. In the 1980’s further animal studies indicated the ability of mild hypothermia to act as a general neuroprotectant following a blockage of blood flow to the brain. This animal data was supported by two landmark human studies published simultaneously in 2002 by the New England Journal of Medicine. Both studies, one occurring in Europe and the other in Australia, demonstrated the positive effects of mild hypothermia applied following cardiac arrest. Responding to this research, in 2003 the American Heart Association (AHA) and the International Liaison Committee on Resuscitation (ILCOR) endorsed the use of therapeutic hypothermia following cardiac arrest. Currently, a growing percentage of hospitals around the world incorporate the AHA/ILCOR guidelines and include hypothermic therapies in their standard package of care for patients suffering from cardiac arrest. Some researchers go so far as to contend that hypothermia represents a better neuroprotectant following a blockage of blood to the brain than any known drug.
Types of ischemic eventsEdit
The data concerning hypothermia’s neuroprotectant qualities following cardiac arrest can be best summarized by two studies published in the New England Journal Medicine. The first of these studies conducted in Europe focused on people who were resuscitated 5-15 minutes after collapse. Patients participating in this study experienced spontaneous return of circulation (ROSC) after an average of 105 minutes. Subjects were then cooled over a 24 hour period, with a target temperature of 32-34°C (89.6-93.2°F). 55% of the 137 patients in the hypothermia group experienced favorable outcomes, compared with only 39% in the group that received standard care following resuscitation. Death rates in the hypothermia group were 14% lower, meaning that for every 7 patients treated one life was saved. Notably, complications between the two groups did not differ substantially. This data was supported by another similarly run study that took place simultaneously in Australia. In this study 49% of the patients treated with hypothermia following cardiac arrest experienced good outcomes, compared to only 26% of those who received standard care.
Most of the data concerning hypothermia’s effectiveness in treating stroke is limited to animal studies. These studies have focused primarily on ischemic as opposed to hemorrhagic stroke, as hypothermia is associated with a lower clotting threshold. In these animal studies, hypothermia represented an effective all purpose neuroprotectant.This promising data has lead to the initiation of human studies. Unfortunately, at the time of this article’s publishing, no results have yet been returned. In terms of feasibility, however, the use of hypothermia to control intracranial pressure (ICP) after an ischemic stroke was found to be both safe and practical. In 2008, long-term hypothermia induced by low-dose hydrogen sulfide, a weak, reversible inhibitor of oxidative phosphorylation, was shown to reduce the extent of brain damage caused by ischemic stroke in rats.
The effects of elevated body temperature following cardiac arrest, stroke, and brain trauma are surprisingly pronounced[How to reference and link to summary or text]. According to one study, elevated body temperature correlated strongly with an extended stay in the ICU for patients suffering from either brain ischemia or brain trauma. Another paper stated that those suffering from either brain trauma or brain ischemia that entered the ICU with a fever had a 14% higher mortality rate than normothermic patients. It appears that the ischemic or traumatized brain is particularly susceptible to the damaging influence of elevated temperature. Combating fever through the use of temperature dampening devices represents a critical aspect of neurological care.
Faced with this extensive array of clinical data, many scientists have attempted to explain the cellular processes responsible for the therapeutic effect of hypothermia following a blockage of blood flow to the brain[How to reference and link to summary or text]. The earliest explanations for why hypothermia acted as a neuroprotectant focused on the slowing of cellular metabolism resultant from a drop in body temperature. For every drop in body temperature of a degree Celsius cellular metabolism slows by 5-7%. Because of this reality, most early theorists believed that hypothermia lessened the harmful effects of oxygen deprivation by decreasing the body’s need for oxygen. The initial emphasis on cellular metabolism explains why the early studies almost exclusively focused on the application of deep hypothermia, as these researchers believed that the therapeutic effects of hypothermia correlated directly with the extent of temperature decline.
More recent data shows that even a modest reduction in temperature can function as a neuroprotectant[How to reference and link to summary or text]. This seems to suggest that hypothermia works on pathways that extend beyond mere metabolism. So while current researchers do not dismiss the fact that cellular metabolism plays a part in the therapeutic value of hypothermia, most have looked for other pathways in hopes of explaining hypothermia’s ability to act as a neuroprotectant.
One of the most promising explanations centers around the series of reactions that occur following oxygen deprivation, particularly those concerning ion homeostasis. In truth, cell death is not caused by oxygen deprivation directly, but rather the cascade of reactions that oxygen deprivation leads to. Cells need oxygen to create ATP--a molecule used by cells to store energy--and cells need ATP to regulate cellular ion levels. Simply, cells use ATP to fuel both the importation of ions necessary for cellular function and the removal of ions that are harmful to cellular function. Without oxygen, cells cannot manufacture the necessary ATP to regulate ion levels and thus cannot prevent the intercellular environment from approaching the ion concentration of the outside environment. It is not oxygen deprivation itself that precipitates cell death, but rather the disruption of homeostasis resultant from oxygen deprivation that leads to cellular apoptosis.
Getting back to hypothermia, it is notable that even a small drop in temperature encourages cell membrane stability during periods of oxygen deprivation. For this reason, a drop in body temperature helps prevent an influx of unwanted ions during an ischemic insult. By making the cell membrane more impermeable, hypothermia helps prevent the cascade of reactions set off by oxygen deprivation. Even moderate dips in temperature strengthen the cellular membrane, helping to minimize any disruption to the cellular environment. It is by moderating the disruption of homeostasis caused by a blockage of blood flow that many now postulate results in hypothermia’s ability to minimize the trauma resultant from ischemic injuries.
The therapeutic effect of hypothermia does not confine itself to metabolism and membrane stability. Another school of thought focuses on hypothermia’s ability to prevent the injuries that occur after circulation returns to the brain, or what is termed reperfusion injuries. An individual suffering from an ischemic insult continues suffering injuries well after circulation is restored. In rats it has been shown that neurons often die a full 24 hours after blood flow returns. Some theorize that this delayed reaction derives from the various inflammatory immune responses that occur during reperfusion. These inflammatory responses cause intracranial pressure, pressure which leads to cell injury and in some situations cell death. Hypothermia has been shown to help moderate intracranial pressure and therefore to minimize the harmful effect of a patient’s inflammatory immune responses during reperfusion. Beyond this, reperfusion also increases free radical production. Many now suspect it is because hypothermia reduces both intracranial pressure and free radical production that hypothermia improves patient outcome following a blockage of blood flow to the brain.
When discussing therapeutic hypothermia it is important to note the various clinical realities associated with this medical procedure. To start, time moderates hypothermia’s effectiveness as a neuroprotectant. Much of the animal data suggests that the earlier hypothermia is induced the better the subject’s outcome. However, therapeutic hypothermia remains partially effective even when initiated as long as 6 hours after collapse. Patients entering a state of induced hypothermia should also receive extensive monitoring from medical professionals. Clinicians must remain watchful of the negative side-effects associated with hypothermia. These side-effects include: arrhythmia, decreased clotting threshold, increased risk of infection, and electrolyte imbalance. The medical data suggests that these side-effects can be mitigated only if the proper protocols are followed. Importantly, medical professionals must avoid overshooting the target temperature, as hypothermia’s negative side-effects increase in severity the lower a patient’s body temperature drops. The accepted medical standards assert that a patient’s temperature should not fall below a threshold of 32°C (89.6°F).
Medical professionals must attempt to minimize a patient's shivering response. For human beings temperature represents one of our most tightly regulated parameters. When body temperature drops below a certain threshold--typically around 36 °C (96.8 °F) --patients will begin to shiver. It appears that regardless of the technique used to induce hypothermia, patients begin to shiver when temperature drops below this threshold. This behavior hinders the ability of medical professionals to induce hypothermia. For this reason, hypothermia should be induced in conjunction with pharmaceuticals that prevent this reaction. The drugs most commonly employed are Desflurane and Demerol. Finally, clinicians should rewarm patients slowly and steadily in order to avoid unhealthy spikes in intracranial pressure. A patient's rewarming should occur at a rate of .5-1 °C an hour in order to avoid injury. In fact, most deaths caused by therapeutic hypothermia occurred during the rewarming phase of the procedure, deaths easily avoided by slow and precise rewarming.
The medical methods through which hypothermia is induced break down into two categories: invasive and non-invasive.
Cooling catheters Edit
Cooling catheters control temperature through invasive internal maneuvering. The process works by inserting a catheter into the femoral vein and placing it near the heart. Once the catheter reaches the heart, a control unit governs the temperature of saline solution circulating through either a metal coated tube or a balloon. The saline cools the patient’s whole body by lowering the temperature of a patient’s blood as it leaves the heart. The main advantage of catheters over other cooling alternatives is their precision and speed. Catheters reduce temperature at rates approaching 4 °C per hour . Through the use of the sophisticated control unit, catheters can bring body temperature to within .1 °C of the target level. This level of accuracy allows doctors to avoid many of the pitfalls associated with excessively deep levels of hypothermia. Furthermore, catheters can raise temperature at steady rate, which helps to avoid harmful rises in intracranial pressure
This invasive technique has been associated with bleeding, infection, vascular puncture, and deep vein thrombosis. Infection caused by cooling catheters is particularly harmful, as resuscitated patients are highly vulnerable to the complications associated with infections.  Bleeding too represents a significant danger to patients, due to a decreased clotting threshold caused by hypothermia. The risk of deep vein thrombosis might be the most pressing medical complication. One study found that incidents of deep vein thrombosis increased by 33% if a patient’s catheter was kept active for 4 days or less and 75% if their catheter was left attached for 4 days or more. Deep vein thrombosis can be characterized as a medical event whereby a blood clot forms in a deep vein, usually the femoral vein. This condition turns deadly when the clot travels to the lungs and causes a pulmonary embolism. Furthermore, catheters, by denying doctors access to the femoral vein, often prevent the administration of other necessary medical procedures. Also, unlike non-invasive alternatives, application of catheters requires the attention and time of a supervising medical doctor. Finding an M.D. has been found to delay catheter insertion by as much as 75 minutes and takes doctors away from other important duties. 
Water blankets Edit
Water blankets are a technology where cold water pushes through a blanket using positive pressure. To lower temperature with optimal speed, medical professionals must cover 80% of a patient’s surface area with water blankets. These blankets are typically augmented by ice packs or cold fans in order to achieve more rapid temperature decline. This technique of temperature management dates back to the 1950’s and represents perhaps the most well studied means of controlling body temperature. Water blankets lower a patient’s temperature exclusively by cooling a patient’s skin and accordingly require no insertion of anything into the patient’s body. Furthermore, nursing professionals can administer water blankets without a supervising M.D.
Water blankets possess several undesirable qualities. First off, they are particularly susceptible to leaking and for this reason represent a serious electrical hazard. Also, water blankets are labor intensive and require near constant monitoring. Water blankets were not designed with sophisticated temperature management in mind and applying water blankets for this purpose requires large amounts of effort on the part of hospital staff. In addition to the labor required, water blankets lower body temperature at a slower rate than other cooling alternatives. Most machines now come with core temperature probes. When inserted into the rectum of the patient, the core body temperature can be monitored. The water blanket can then be adjusted to the desired temperature set by the healthcare provider. Which, in return, allows for a more accurate temperature range. Also, water blankets can cool patients less precisely than alternative methods. Water blankets tend to overshoot the target temperature and cool patients to levels below 32 °C (89.6 °F). Hypothermia’s negative side-effects increase in prevalence the lower a patient’s body temperature drops, making unnecessary fluctuations in temperature detrimental to patient health. Likewise, due to their imprecision, water blankets often rewarm patients at too quick a rate. This leads to spikes in intracranial pressure, spikes that can cause serious brain injury and in some instances patient mortality.
Recently there has been an advance in non-invasive technology embodied by a medical device called the Arctic Sun. The Arctic Sun attempts to combine the non-invasive nature of water blankets with the precision and speed of catheters. The Arctic Sun consists of a control module and connected gel pads. The gel pads stick to a patient’s body using an adhesive called hydrogel—a substance that adheres to the skin without removing hair follicles. When cooling a patient, the Arctic Sun’s gel pads cover only 40% of a patient’s surface area, leaving most of the patient’s body free for augmenting medical procedures. A control module using negative pressure circulates water through these pads at a temperature between 4-42°C (39.2-107.6°F). Water is pulled through the pads rather than pushed, which in turn minimizes the risk of leakage. By controlling the temperature of the water running through the gel pads, the Arctic Sun’s control module can effectively bring a patient’s temperature to the desired level at a rate of 1.5 °C an hour. Through the use of a sophisticated computer algorithm, the Arctic Sun can achieve accuracy of .2 °C with minimal monitoring from medical professionals. This precision allows for slow and methodical rewarming and prevents excessive jumps in intracranial pressure. However, due to the Arctic Sun’s noninvasive nature, this precision is achieved without the host of side effects associated with invasive procedures such as cooling catheters.
A serious complaint levied against the Arctic Sun relates to the risk of skin injury. Indeed, a study found that one in ten thousand patients treated with the Arctic Sun suffered from some form of skin incidence. Other researchers claim that catheters can lower body temperature at a faster rate, which is relevant because most of the clinical data suggests that the sooner cooling is initiated the better a patient’s outcome. However, the research shows a wide variations in the cooling speeds of all devices, variation caused by the specifics of a patient’s condition and sedation protocols. Furthermore, there exists a 75 minute delay on average between admittance and catheter insertion by an M.D, while the Arctic Sun, like water blankets, can be administered by unsupervised nursing professionals. So although the catheters cool at a quicker rate, because of early administration, most studies find that patients treated with the Arctic Sun reached their target temperature at roughly the same time after collapse as those treated with catheters.
The use of hypothermia for therapeutic purposes represents a technique with increasing levels of application. Virtually unknown a few decades ago, it is now part of the standard package of care for the thousands of individuals suffering from cardiac arrest every year. Yet with human studies concerning hypothermia’s effectiveness in treating ischemic stroke and brain trauma in the process of being completed, it appears that the current therapeutic uses of hypothermia represent only the tip of the iceberg.
- ↑ 1.0 1.1 1.2 1.3 1.4 1.5 1.6 1.7 1.8 [Polderman, Kees H. “Application of therapeutic hypothermia in the ICU.” Intensive Care Med. (2004) 30:556-575. http://www.springerlink.com/content/9n1h8x2bj8vcc5b8/]
- ↑ 2.0 2.1 2.2 Holzer, Michael. “Mild Hypothermia to Improve the Neurologic Outcome After Cardiac Arrest.” New England Journal of Medicine. (2002) Vol. 346, No. 8.
- ↑ Therapeutic Hypothermia After Cardiac Arrest: An Advisory Statement by the Advanced Life Support Task Force of the International Liaison Committee on Resuscitation - Nolan et ...
- ↑ 4.0 4.1 4.2 4.3 4.4 Sessler, Daniel. “Thermoregulation and Heat Balance.” Therapeutic Hypothermia. Ed. Mayer, Stephen and Sessler, Daniel. Marcel Decker: New York, 2005.
- ↑ Bernard, Stephen et al. "Treatment of Comatose Survivors of Out-of-Hospital Cardiac Arrest with Induced Hypothermia." New England Journal of Medicine. (2002) Vol. 346, No. 8. http://content.nejm.org/cgi/content/abstract/346/8/557
- ↑ Krieger, Derk. et al.“Cooling for Acute Ischemic Brain Damage.” American Heart Association. May 25, 2001, pg. 1847-1854
- ↑ Schwab, S. et al. “Moderate Hypothermia in the Treatment of Patients with Severe Middle Cerebral Artery Infarction.” American Heart Association. July 31, 1998, pg. 2461-2466 http://cat.inist.fr/?aModele=afficheN&cpsidt=1604537
- ↑ Florian B, Vintilescu R, Balseanu AT, Buga A-M, Grisk O, Walker LC, Kessler C, Popa-Wagner A (2008). Long-term hypothermia reduces infarct volume in aged rats after focal ischemia. Neuroscience Letters 438: 180–185.
- ↑ Dringer, Michael et al. “Elevated body temperature independently to increased length of stay in neurological intensive care unit patients.” Critical Care Medicine. 2004 Vol. 32, No. 7, pg. 1489-1495
- ↑ 10.0 10.1 Kammersgaard, L.P. et al. “Admission Body Temperature Predicts Long-Term Mortality After Acute Stroke http://stroke.ahajournals.org/cgi/content/abstract/33/7/1759.” American Heart Association. March 12, 2002, pg. 1759-1762.
- ↑ Ginsberg, Myron et al. “Combating Hyperthermia in Acute Stroke.” American Association. November 10, 1997, pg. 529-534. http://stroke.ahajournals.org/cgi/content/abstract/29/2/529
- ↑ Polderman, Kees. “Induced hypothermia and fever control for prevention and treatment of neurological injuries.” Lancet. 2008; 371: 1955–69. http://www.tripdatabase.com/spider.html?itemid=714708
- ↑ 13.0 13.1 Adler, Jerry. “Back From the Dead.” Newsweek. July 23, 2007. http://www.accessmylibrary.com/coms2/summary_0286-32455420_ITM
- ↑ 14.0 14.1 14.2 14.3 Calver, Patty. “The Big Chill.” RN. (2005) Vol. 68, No. 5 http://rn.modernmedicine.com/rnweb/article/articleDetail.jsp?id=158219
- ↑ Schwab, Stefan et al. “Feasibility and Safety of Moderate Hypothermia After Massive Hemisphere Infarction.” American Heart Association. June 4, 2001, pg. 2033-2035.
- ↑ Schwab, Stefan et al. “Feasibility and Safety of Moderate Hypothermia After Massive Hemisphere Infraction.”
- ↑ 17.0 17.1 [Haugk, Moritz et al. “Feasibility and efficacy of new non-invasive cooling device in post resuscitation intensive care medicine.” Resuscitation (2007) 75, 76-81]
- ↑ [Simosa, Hector et al. “Increased Risk of Deep Venous Thrombosis with Endovascular Cooling in Patients with Traumatic Head Injury."]
- ↑ 19.0 19.1 [(Sterz-Dept of Emergency Medicine, Medical University of Vienna March 2007
- ↑ Holden, Mary et al. "Clinically Induced Hypothermia: Why Chill Your Patient?" Advanced Critical Care. (2006) Vol. 17, No. 2, pg. 125-132. http://www.ncbi.nlm.nih.gov/pubmed/16767013
- ↑ Holden, Mary et al. "Clinically Induced Hypothermia: Why Chill Your Patient?" Advanced Critical Care. (2006) Vol. 17, No. 2, pg. 125-132. http://www.ncbi.nlm.nih.gov/pubmed/16767013